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ABSTRACT OF THE DISSERTATION 
 
Characterization of a Novel NPC1I1061T Knock-in Mouse Model of Niemann-Pick Type C1 Disease 
by 
Maria Praggastis 
Doctor of Philosophy in Biology and Biomedical Sciences  
Molecular Cell Biology  
Washington University in St. Louis, 2014 
Professor Daniel Ory, Chair 	  
Niemann-Pick Type C (NPC) disease is a fatal pediatric cholesterol storage disease that is 
caused by mutations in either the npc1 or npc2 genes.  Loss of function of either gene results in toxic 
storage of free cholesterol in the lysosomes due to a cholesterol trafficking defect.  In humans the free 
cholesterol accumulation leads to Purkinje cell loss in the cerebellum and is accompanied by 
neurodegenerative symptoms that include ataxia, vertical supranuclear gaze palsy, and decreased motor 
function.  Most NPC1 patients succumb to the disease within the first two decades of life. 
The most prevalent mutation, NPC1I1061T, resides within the cysteine-rich luminal domain of the 
NPC1 protein and represents 18-23% of all disease alleles. Previous studies from our laboratory have 
shown that the NPC1I1061T protein exhibits a markedly reduced half-life as compared to wild-type NPC1 
due to protein misfolding and consequent targeting for endoplasmic reticulum (ER)-associated 
degradation (ERAD). More recently, ryanodine receptor antagonists have been shown to increase 
NPC1I1061T protein stability and reduce cholesterol storage in human skin fibroblasts homozygous for the 
NPC1I1061T mutation. Histone deacetylase (HDAC) inhibitors have also been shown to augment 
NPC1I1061T protein and cholesterol egress from the lysosome, possibly via an increase in HSP90 
expression. Together, these findings raise the possibility that small molecule-based proteostatic therapies 
might stabilize mutant NPC1 proteins and have the potential to provide clinical benefit. 
To address the need for an animal model in which to test proteostatic therapies for NPC1 
disease, we generated a NPC1I1061T knock-in mouse model. In comparison to the BALB/c NPCnih (Npc1-/-) 
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mouse, this mouse models a less severe form of NPC1 disease and displays hallmarks of NPC1 disease, 
including weight loss, decreased motor coordination, Purkinje cell death, and lysosomal lipid 
accumulation in brain and liver. We show that the murine NPC1I1061T protein has a markedly reduced half-
life in vivo, which is consistent with protein misfolding and rapid ER-associated degradation and can be 
stabilized by HDAC inhibition. This novel mouse model faithfully recapitulates disease caused by the 
human NPC1I1061T mutation, and provides the field with a powerful tool for pre-clinical evaluation of 
proteostatic therapies for NPC1 disease. 
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Chapter 1: Background and Introduction 
1.  Niemann-Pick Type C disease 
1.1 Human disease 
Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disease caused by a defect in 
lysosomal cholesterol transport that results in Purkinje cell death in the cerebellum. 95% of NPC disease 
results from mutations in the NPC1 gene, while the remaining cases are caused by mutations in NPC2 
(Ory, 2000). NPC1 disease is characterized by accumulation of cholesterol and other lipids in the viscera 
and central nervous system (Ory, 2000; Walkley and Suzuki, 2004). NPC1 patients typically present in 
early childhood with ataxia, dystonia, weight loss, progressive impairment of motor and intellectual 
function, and usually die within the first two decades of life (Vanier, 2010). There are currently no FDA-
approved therapies for this disorder. 
 
1.2 NPC1 protein function 
The NPC1 gene encodes a polytopic, highly glycosylated transmembrane protein with homology 
to Patched1, HMG-CoA Reductase, and SCAP (Carstea et al., 1997; Davies and Ioannou, 2000) that 
localizes to the limiting membrane of the late endosome/lysosome. In addition to the conserved sterol-
sensing motif, the NPC1 protein contains a leucine zipper and a lysosomal targeting motif. The N-terminal 
domain of NPC1 binds unesterified cholesterol within the lysosome, interacting with NPC2 and facilitating 
cholesterol egress via an undefined mechanism (Infante et al., 2008; Kwon et al., 2009; Millard et al., 
2000). Recently, a second sterol-binding site outside of the N-terminal domain has been discovered that 
can bind several oxysterol derivatives (Ohgane et al., 2013). The function and exact location of this site 
within the protein is yet unknown.  
 
1.3 Disease-causing mutations within the cysteine-rich domain of NPC1 
 Over 300 mutations have been documented throughout the NPC1 gene. These mutations include 
truncations associated with the severe infantile-death phenotype and many missense mutations that 
encode proteins with varying degrees of biochemical dysfunction (Carstea et al., 1997; Greer et al., 1999; 
Millat et al., 2001; Park et al., 2003). The necessary function of the sterol-sensing domain in NPC1 is 
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underscored by the fact that mutations located within this domain express very little NPC1 protein and are 
correlated with severe neurological phenotype (Millat et al., 2001; Yamamoto et al., 2000). 35% of the 
mutations documented in North America are localized to the cysteine-rich domain of the NPC1 protein, 
including NPC1G992W and NPC1I1061T. These mutations occur with higher frequency due to founder effects 
in Nova Scotia and the Upper Rio Grande valley, respectively (Carstea et al., 1997; Greer et al., 1998; 
Millat et al., 1999). However, most NPC1 patients are unique haplotypes, as 80% of NPC1 patients are 
compound heterozygotes, and only 7% are homozygous (Park et al., 2003).  
 
1.4 NPC1I1061T mutation 
The most common human NPC1 mutation, NPC1I1061T, is localized to the cysteine-rich domain 
and represents 15-20% of all human disease alleles (Davies and Ioannou, 2000; Millat et al., 1999; Park 
et al., 2003). The I1061T mutation is clinically associated with juvenile-onset of the disease and has a 
biochemically moderate defect in cholesterol esterification. Preliminary studies of NPC1I1061T reported that 
this mutation results in decreased NPC1 protein levels and an enhanced electrophoretic mobility on 
western blot, and overexpression of the NPC1I1061T protein results in complementation of the mutant 
phenotype (Gelsthorpe et al., 2008; Watari et al., 2000). While NPC1I1061T protein retains partial 
cholesterol trafficking function, it is Endoglycosidase H (Endo H) sensitive and localized to the ER. 
Metabolic labeling of NPC1 protein in human skin fibroblasts (HSFs) shows that NPC1I1061T has a 
decreased half-life, and treating NPC1I1061T with proteasomal inhibitor increases accumulation of 
NPC1I1061T protein (Gelsthorpe et al., 2008). These data demonstrate that the NPC1I1061T mutation 
encodes a partially functional protein that is misfolded and targeted for ER-associated degradation 
(ERAD). Overexpression of the NPC1I1061T protein results in lysosomal localization of the mutant protein, 
likely due to a small proportion of the newly synthesized NPC1I1061T protein that is able to assume proper 
conformation and escape the ER quality control checkpoints (Gelsthorpe et al., 2008). 
1.5 Lysosomal lipid accumulation in NPC1 disease 
Cells harboring inactivating mutations in NPC1 sequester unesterified cholesterol in lysosomes 
and exhibit marked impairment of mobilization and re-esterification of low-density lipoprotein (LDL) 
cholesterol (Millard et al., 2000; Neufeld et al., 1999; Wojtanik and Liscum, 2003). Lack of cholesterol 
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egress from the lysosome causes ER cholesterol depletion, activating the de novo cholesterol 
biosynthetic pathway and increasing transcription of genes involved in cholesterol uptake (Brown and 
Goldstein, 1997; Kristiana et al., 2008; Liscum and Faust, 1987; Radhakrishnan et al., 2008). Lysosomal 
accumulation of free cholesterol also causes overall lipid trafficking dysfunction in the lysosome and 
inhibition of other lipid regulatory proteins such as acid sphingomyelinase and glucocerebrosidase 
(Reagan et al., 2000). The most predominant lipids stored in NPC1 deficient liver are free cholesterol, 
ceramides, and sphingoid bases, while the brain accumulates gangliosides and sphingomelins (Butler et 
al., 1993; Fan et al., 2013; Goldin et al., 1992; Pentchev et al., 1985; Rodriguez-Lafrasse et al., 1994). 
The overall quantity of cholesterol in the brain does not increase in NPC1 disease due to loss of 
cholesterol via demyelination of neurons. NPC1-/- mice show the most cholesterol depletion in areas with 
high myelination such as the midbrain, brainstem, and spinal chord (Li et al., 2005). However, 
histochemical staining of brain sections from NPC1-/- mice reveals subcellular accumulation of free 
cholesterol in the brain. This indicates that there is lysosomal storage of cholesterol in brain tissue 
(Dietschy and Turley, 2004; Reid et al., 2004; Xie et al., 2000). 
 
1.6 Neurodegeneration in NPC1 disease 
 The toxic storage of lysosomal lipids in NPC1 disease causes upregulation of the autophagic 
pathway in neurons. This process can be identified by increased LC3-II expression and increased 
autophagosome content as seen by EM (Ko et al., 2005). NPC1 deficient brains also have increased 
expression of cytokines, including MIP1-α, TNF-α, and Glial Fibrillary Acidic Protein (GFAP), resulting in 
inflammation and microglial activation (Li et al., 2005; Lopez et al., 2012). This glial activation has been 
shown to be a beneficial response to neuronal stress, since deletion of the MIP1-α gene in NPC1-/- mice 
exacerbates the neurodegeneration phenotype (Lopez et al., 2012). The current accepted model is that 
lack of NPC1 activity results in autophagic cell death in neurons, and glial cells are activated to absorb 
the cell debris. This theory is supported by the fact that glial cells aggregate at sites where Purkinje cell 
death has occurred (Ko, 2005). 
While there is neurodegeneration throughout the brain in NPC1 disease, the Purkinje cells are 
particularly susceptible to autophagy because they are more sensitive to the insufficient levels of sterols 
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caused by the cholesterol trafficking defect (Ko et al., 2005). Neurodegeneration in NPC1 disease is cell-
autonomous, as shown by cell type-specific rescue experiments in NPC1-/- mice, as well as studies in 
chimeric mice (Ko et al., 2005; Lopez et al., 2011). While Purkinje cell-specific NPC1 rescue will prevent 
neurodegeneration in the cerebellum, broad rescue of all neuronal cell types is required to completely 
rescue the disease phenotype (Lopez et al., 2011). Furthermore, astrocyte- or visceral-specific NPC1 
deletion does not cause neuropathy in mice, which indicates that it is the cell-autonomous death of 
neurons that is responsible for the behavioral phenotype in NPC1 disease (Yu et al., 2011).  
 
2. Development of NPC1 disease therapies 
2.1 Current therapies 
 While there are currently no FDA-approved therapies for NPC1 disease, most patients in the US 
receive off-label treatment of Miglustat, an inhibitor of glucosylceramide synthase originally developed for 
Gaucher disease. NPC1-/- mice treated with Miglustat display improved motor coordination, increased 
longevity, and increased Purkinje cell survival due to a decrease in the accumulation of GM2 and GM3 
gangliosides in the brain (Zervas et al., 2001). Miglustat was approved for treatment of NPC1 disease in 
the European Union in 2009 after several clinical studies demonstrated stabilization of neurological 
symptoms with treatment (Patterson et al., 2012; Patterson et al., 2010; Patterson et al., 2007; Wraith et 
al., 2010). However, Miglustat provides limited clinical benefit, and further development of therapeutics 
that directly ameliorate the primary cholesterol trafficking defect is needed. 
The most promising therapeutic for NPC1 disease to emerge from preclinical studies is 
cyclodextrin. Cyclodextrins are cyclic oligosaccharides commonly used as a drug delivery system for 
hydrophobic compounds because of their amphipathic barrel structure. In the context of NPC1 disease, 
“unloaded” β-cyclodextrin binds to free cholesterol, allowing its egress from the lysosomal compartment 
and excretion from the body as bile acid (Liu et al., 2010). NPC1-/- mice treated with intraperitoneal 
injections of 2-hydroxypropyl-β-cyclodextrin (HPBCD) display a 63% increase in lifespan and decreased 
accumulation of free cholesterol and gangliosides in the brain and peripheral tissues (Davidson et al., 
2009; Liu et al., 2010; Ramirez et al., 2010). Similar results were seen upon treatment in NPC2-/- mice, 
indicating that this effect is independent of NPC1 protein function (Davidson et al., 2009). Unlike 
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Miglustat, which has high blood-brain barrier permeability, very little of systemically delivered HPBCD 
reaches the brain (Pontikis et al., 2013; Treiber et al., 2007). HPBCD’s poor permeability results in the 
need to administer very high doses. Unfortunately, high concentration of HPBCD in the peripheral tissues 
has been shown to cause deafness a cat model of NPC1 disease (Ward et al., 2010). This toxicity, as 
well as the potential complications of direct delivery to the CNS, provide challenges to development of 
HPBCD as a treatment for NPC1 disease.  
 
2.2 Proteostatic therapies 
 Current efforts for NPC1 drug discovery are focused on proteostatic therapies. In order to 
maintain cell health and homeostasis, cells regulate an intricate network of proteins and signaling 
pathways to control protein synthesis, folding, function, and degradation (Balch et al., 2008; Douglas and 
Dillin, 2010; Powers et al., 2009). This system, referred to as the proteostasis network, is made up of over 
1,000 factors and can be dynamically regulated in response to genetic mutations, environmental stress, 
and aging (Prahlad et al., 2008; Prahlad and Morimoto, 2009). A well-established branch of the 
proteostasis network is the regulation of protein folding in the ER. Proteins in the UPR and ERAD 
pathways are activated to alleviate cellular stress caused by protein misfolding. These processes either 
stabilize the misfolded protein and return it to its native conformation or target the protein for proteasomal 
degradation. Altering regulators of the proteostasis network via small molecules or genetic manipulation 
to restore protein folding has been fruitful in several disease models, including cystic fibrosis and 
Alzheimer’s disease (Cohen et al., 2006; Grove et al., 2009). 
 Recently, ryanodine receptor antagonists have been shown to increase NPC1I1061T protein 
stability and reduce cholesterol storage through activation of Calnexin in human skin fibroblasts 
homozygous for the NPC1I1061T mutation (Yu et al., 2012). Histone deacetylase (HDAC) inhibitors have 
also been shown to augment NPC1I1061T protein and cholesterol egress from the lysosome, possibly via 
an increase in HSP90 expression (Budillon et al., 2005; Kim et al., 2007; Munkacsi et al., 2011; Pipalia et 
al., 2011). Together, these findings raise the possibility that small molecule-based proteostatic therapies 
might stabilize mutant NPC1 proteins and have the potential to provide clinical benefit. 
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2.3 Established animal models 
 Many of the prominent neuropathological features of human NPC1 disease (e.g., neuronal lipid 
storage and progressive loss of Purkinje cells) are modeled in the BALB/c NPCnih (NPC1-/-) mouse, a 
spontaneously occurring inbred mouse that harbors a retroposon insertion in the Npc1 gene (Higashi et 
al., 1993; Loftus et al., 1997). This mouse model, however, does not synthesize NPC1 protein and 
therefore is not amenable to proteostatic therapies (Morris et al., 1982; Pentchev et al., 1980; Shio et al., 
1982). A second naturally occurring mouse model, NPC1nmf164, which expresses a spontaneously 
generated D1005G amino acid substitution in the NPC1 protein, was recently reported (Maue et al., 
2012). While the NPC1nmf164 mice exhibit a delayed onset NPC1 phenotype, the D1005 residue is not 
conserved in the human protein and there is no evidence that the mutation affects protein folding or 
stability. Development of proteostatic therapies for NPC1 disease requires testing candidate therapies in 
a suitable disease model. To address the need for an animal model in which to test proteostatic therapies 
for NPC1 disease, we generated a NPC1I1061T knock-in mouse model. 
 
3.  Dissertation summary 
 In this work, I report that several disease-causing mutations within the cysteine-rich loop of NPC1 
encode proteins that are misfolded and degraded, similar to NPC1I1061T. Other NPC1 mutants are 
identified as partially functional. This data provides evidence that chemical chaperone treatments could in 
theory benefit patients harboring a variety of NPC1 mutant alleles. To address the need for an animal 
model in which to test proteostatic therapies for NPC1 disease, we generated a NPC1I1061T knock-in 
mouse model. In comparison to the BALB/c NPCnih (NPC1-/-) mouse, this mouse models a less severe 
form of NPC1 disease and displays hallmarks of NPC1 disease, including weight loss, decreased motor 
coordination, Purkinje cell death, and lysosomal lipid accumulation in brain and liver. We show that the 
murine NPC1I1061T protein has a markedly reduced half-life in vivo, which is consistent with protein 
misfolding and rapid ER-associated degradation, and can be stabilized by HDAC inhibition. This novel 
mouse model faithfully recapitulates disease caused by the human NPC1I1061T mutation and provides a 
powerful tool for pre-clinical evaluation of proteostatic therapies for NPC1 disease. 
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Chapter 2: Identification of disease-causing NPC1 mutations that encode misfolded proteins 
2.1 Introduction 
More than 300 disease-causing missense mutations have been identified in the NPC1 gene. We 
previously have shown that the NPC1I1061T protein is misfolded, targeted for ER-associated degradation 
(ERAD), and degraded in the proteasome (Gelsthorpe et al., 2008). The NPC1I1061T mutant is the first to 
be characterized as misfolded and partially functional, and we hypothesized that many of the other 
missense mutations, particularly in the cysteine-rich domain of the NPC1 protein, cause disease via a 
similar mechanism. 
In recent years, small molecule chaperones have gained interest as potential therapeutics for 
many neurodegenerative diseases, including Alzheimer, Parkinson, and Huntington disease (Douglas 
and Dillin, 2010). In addition, high-throughput screening has identified several chemical chaperones that 
stabilize the mutant CFTR protein ΔF508, an allele that causes 90% of cystic fibrosis disease 
(Pedemonte et al., 2005). CFTR ΔF508 and NPC1I1061T are quite similar, in that they are both large, 
transmembrane proteins that are highly glycosylated and targeted for ERAD because of misfolding 
(Denning et al., 1992; Du et al., 2005; Gelsthorpe et al., 2008; Kopito, 1999; Lukacs et al., 1994). We 
hypothesized that the same small molecules that stabilize CFTR ΔF508 protein could also stabilize 
NPC1I1061T, ameliorating the cholesterol trafficking phenotype. 
 
2.2 Methods 
Generation of NPC1 mutant constructs. The cDNA sequence of wild-type (WT) human NPC1 was cloned 
into the pMD2.1 vector (Ory et al., 1996) via the BamHI and SacII restriction sites. The cysteine-rich 
domain of NPC1 was also cloned into the pSL301 shuttle vector via the SphI and SacII restriction sites for 
mutagenesis. NPC1 mutants were generated in the pSL301 vector via site directed mutagenesis 
(Quikchange II kit, Agilent) using listed primers (Table 2.1). Mutant NPC1 SphI-SacII fragments were then 
shuttled back into the pMD2.1 NPC1 to create the final expression vectors. 
 
Transient transfection of NPC1 mutant constructs. NPC1-/- CHO cells (M12 cell line; (Millard et al., 2000)) 
were plated at 30% confluence in 6cm plates in media containing 1:1 Dulbecco's modified Eagle's 
medium: Ham’s F-12, 5% (v/v) fetal calf serum, 2 mm glutamine, 50 units/ml penicillin, and 50 µg/ml 
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streptomycin. Cells were transfected with 5µg of NPC1 mutant pMD2.1 plasmid with Lipofectamine 
reagent (Life Technologies # 18324020). 48hrs post transfection, cells were plated on 12mm circular 
coverslips in media in 24-well plates, 5x104 cells per well. 72hrs post transfection, cells were fixed in 4% 
paraformaldehyde for 20min, then permeabilized with 0.2% Saponin in PBS with 10% normal goat serum. 
Cells were stained with α-NPC1 antibody (rabbit, (Millard et al., 2000)) 1:500, and Filipin (Sigma) 
0.05mg/mL for 1hr. Cells were incubated with rabbit Alexafluor 594 1hr, then mounted with Slowfade (Life 
Technologies). Cells were examined by fluorescence microscopy on a Zeiss Axiovert epifluorescence 
microscope. Cells were binned as either fully, partially, or not complementing the cholesterol trafficking 
phenotype as seen by filipin staining. Mutants with at least 10% full complementation were considered 
partially functional. 
 
Small molecule chaperone treatment of NPC1 mutant human skin fibroblasts. Human skin fibroblasts 
(HSFs) derived from NPC1 patients harboring NPC1P887L and NPC1S954L mutations of interest were 
obtained (Garver et al., 2010; Greer et al., 1998). Cells were plated in regular media (10% inactivated 
fetal calf serum, 2 mm glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin) 24hrs before 
treatment. Cells were then treated with compounds in a concentration curve of 1-10µM or with 0.1% 
DMSO vehicle in regular media for 48hrs for protein assays, or 7 days for cholesterol assays. 
 
Real–time quantitative RT-PCR. RNA was harvested by homogenization in Trizol reagent (Invitrogen) as 
per manufacturer protocol. cDNA libraries were made via the Superscript III First Strand Synthesis 
System (Invitrogen) with provided oligo dT primers. qRT-PCR analysis was performed with reported 
primer sequences (Gelsthorpe et al., 2008). Relative quantification of gene expression was performed 
using the comparative threshold (CT) method as previously described (Millard et al., 2005). Fold changes 
in mRNA expression level were calculated following normalization to 36B4, a ribosomal mRNA. 
 
Protein preparation and western blot analysis. Cultured cells were harvested in RIPA buffer (10mM Tris-
Cl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, and 140 
mM NaCl) with Complete Protease Inhibitor Mixture (Roche) and 1 mM phenylmethylsulfonyl fluoride and 
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incubated on ice for 10 minutes. Post-nuclear supernatant was obtained by centrifuging for 10 minutes at 
12,000g at 4oC. Protein concentration was quantified using the BCA Protein Assay Kit (Pierce). Non-
boiled protein samples were resolved by 7.5% SDS-PAGE under reducing conditions. Proteins were 
transferred onto polyvinylidene difluoride (0.45 mm; Millipore) using a semi-dry electroblotter (Owl 
Scientific). Western blot analysis was performed using an affinity purified rabbit anti-human NPC1 
antibody at a dilution of 1:5000  (Millard et al., 2000) and rabbit anti-human Actin (Sigma a2066) at a 
dilution of 1:5000. Detection was performed by chemiluminescence using a peroxidase-conjugated 
donkey anti-rabbit IgG (Jackson Immunoresearch) at 1:5000. 
 
Endoglycosidase treatments. Protein samples were incubated with Endoglycosidase H (New England 
Biolabs) or PNGaseF (New England Biolabs) for 7 hours at 37oC in 5mM sodium phosphate with 1% NP-
40. 
 
Quantification of free cholesterol. Sample preparation, instrumentation, and quantification of free 
cholesterol were performed by tandem mass spectrometry as described previously (Fan et al., 2013). 
 
Statistics. 
Statistical significance was calculated via two-tailed t-test using the Holm-Sidak method, with p <0.05 
considered to be significant.  
 
2.3 Results 
Identifying partially functional NPC1 mutant proteins via complementation screen. To identify other 
disease-causing mutations within the cysteine-rich domain of the NPC1 protein that retain partial function, 
I conducted an immunofluorescence-based complementation screen. A vector library of 40 plasmids was 
generated that included documented missense mutations within this domain of the NPC1 protein (Carstea 
et al., 1997; Greer et al., 1999; Millat et al., 1999; Millat et al., 2001; Park et al., 2003; Ribeiro et al., 2001; 
Yamamoto et al., 2000) (Table 2.1, Figure 2.1). These mutant constructs were each transiently expressed 
in NPC1-/- CHO cells (M12 cell line	   (Millard et al., 2000), and cholesterol trafficking function was 
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determined via filipin, a free cholesterol label. While cells expressing WT NPC1 protein were filipin 
negative, cells expressing the P691S negative control plasmid were filipin positive (Figure 2.2). NPC1P691S 
protein localized to the limiting membranes of free cholesterol-laden vesicles, indicating that this protein 
localizes appropriately to the lysosome and is not retained in the ER. Five of the NPC1 mutants tested, 
P887L, S954L, G992R, G1012D, and H1016R, encoded proteins that had at least 10% full 
complementation and overall resulted in partial complementation of the cholesterol trafficking phenotype 
(Figures 2.2 and 2.3). The staining pattern of NPC1P887L is similar to NPC1I1061T in that they both have 
some granular, perinuclear localization, as well as some vesicular staining. The S954L, G992R, G1012D 
and H1016R mutants appear to have a vesicular staining pattern in the context of overexpression.  
To further characterize these mutants of interest, I obtained human skin fibroblasts (HSFs) from 
NPC1 patients harboring the P887L and S954L mutations. While NPC1I1061T, NPC1P887L, and NPC1S954L 
fibroblasts expressed NPC1 mRNA at the same or higher levels when compared to WT fibroblasts, NPC1 
protein expression was greatly decreased (Figure 2.4). Treating fibroblasts with 10% glycerol to aid in 
protein folding or with Velcade, a proteasomal inhibitor, increased NPC1 mutant protein levels (Figure 
2.4). Immunofluorescence staining revealed that NPC1P887L does not colocalize with LAMP1, a lysosomal 
marker, while a portion of NPC1S954L protein does. These data indicate that, while both proteins are 
misfolded and can be stabilized via small molecular chaperones, the I1061T and P887L mutants have a 
more severe folding defect than S954L (Figure 2.5).  
While HSFs were not available for other mutants of interest, I did show that transiently expressed 
NPC1G992R protein is Endo H-sensitive and produced a similar banding pattern to NPC1I1061T in NPC1-/- 
CHO cells, demonstrating that this mutant protein is retained in the ER and does not mature through the 
secretory pathway (Figure 2.4). NPC1G1012D and NPC1H1016R appear to be partially Endo H-resistant, 
indicating that either the folding defect is not as severe as in NPC1I1061T or the protein is partially 
functional and not misfolded. Increasing NPC1G1012D and NPC1H1016R protein abundance via proteostatic 
treatments would still be beneficial, since we have shown that overexpression of both of these mutants 
complement the null phenotype (Figure 2.2). 
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Stabilizing NPC1 mutant protein with small molecule chaperones. Since the NPC1I1061T protein was 
characterized as misfolded, there has been much interest in the development of protein stabilizing 
treatments for NPC1 disease. Our data from the complementation screen indicates that many NPC1 
patients harboring cysteine-rich domain missense mutations would also benefit from treatment with small 
molecule chaperones. To this end, we screened a candidate library of small molecules predicted to aid in 
protein folding in NPC1 mutant HSFs. Our chemical library included compounds shown to stabilize the 
CFTR ΔF508 protein, as well as molecules that have been found to improve protein folding in yeast, 
kindly provided by FoldRx (Pfizer). While several small molecules increased NPC1 mutant protein levels 
in NPC1I1061T and NPC1P887L HSFs, we did not see any significant change in free cholesterol 
accumulation (Figure 2.6). These data indicate that the small molecule chaperones increased the total 




 The human NPC1I1061T allele encodes a misfolded protein that is localized to the ER and retains 
partial cholesterol trafficking function (Gelsthorpe et al., 2008). While it is the most common NPC1 
mutation, 80% of NPC1 patients are compound heterozygotes (Park et al., 2003). To determine whether 
other disease-causing mutations within the cysteine-rich domain of NPC1 are also partially functional and 
would be candidates for proteostatic therapy, we performed a complementation screen in M12 cells. We 
identified several mutants that retain partial cholesterol trafficking function and have decreased 
accumulation of NPC1 protein in patient-derived HSFs. Our data indicate that NPC1P887L and NPC1G992R 
have phenotypes very similar to NPC1I1061T with enhanced electrophoretic mobility, lack of colocalization 
with lysosomal marker LAMP1, and Endo H-sensitivity indicative of ER localization. NPC1S954L, 
NPC1G1012D, and NPC1H1016R are also partially functional, but appear to mature through the ER and reach 
the lysosome. These mutants are still candidates for proteostatic therapies, since the complementation 
screen shows that increasing abundance of these NPC1 proteins alleviates the cholesterol trafficking 
phenotype. 
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 In order to identify small molecule chaperones that increase the stability of mutant NPC1 protein, 
we screened a library of candidate chaperones previously shown to improve protein folding. While we 
identified four compounds that increased NPC1I1061T and NPC1P887L protein abundance, there was no 
change in the cholesterol trafficking phenotype as seen by free cholesterol quantification. This result 
demonstrates that these compounds are not assisting the NPC1 protein maturation through the secretory 
pathway and allowing it reach the lysosome. It is possible that increasing the concentration of chaperone 
above 10µM may increase mutant NPC1 protein function. However, preliminary studies with 30µM 
compound indicate that there is toxicity and cell death at higher concentrations. In addition, we are 
interested in identifying compounds with a lower EC50 in order to produce more potent therapeutics. In the 
time since we conducted these studies, our collaborators have had success rescuing the NPC1 
phenotype via ryanodine receptor antagonists, HDACi, and oxysterol derivatives (Ohgane et al., 2013; 
Pipalia et al., 2011; Yu et al., 2012). We are interested in taking these studies forward and testing these 
compounds in an in vivo model of NPC1 disease.  
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Table 2.1: Disease-causing missense mutations within the NPC1 cysteine-rich domain. 
Mutagenesis primers used in the NPC1 mutant complementation screen. Mutant constructs were 
transfected are designated by a checkmark in the “tested” column, and the NPC1 function is listed in the 
“complementation” column. 
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Figure 2.1: Schematic of the NPC1 protein. NPC1 is localized to the limiting membrane of the 
lysosome with 13 transmembrane domains (TMDs) that span the lipid bilayer. The sterol-sensing domain 
(SSD) is composed of TMDs 3-7. The cholesterol-binding N-terminal domain (NTD), Loop 1 region (L1), 
and cysteine-rich domain (C-rich) are on the luminal side of the membrane. Mutated residues that are 
characterized in this screen are highlighted in red, and I1061T is highlighted in green.  
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Figure 2.2: Partially functional NPC1 
mutants complement the NPC1-/- 
phenotype. NPC1 mutant constructs 
were transfected into M12 cells, then 
stained for NPC1 protein (red) and free 
cholesterol (filipin, blue), and imaged via 
fluorescence microscopy. Exposure time 
for filipin is 50ms for all images while 
exposure times for NPC1 were optimized 
for each mutant.  
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Figure 2.3: Quantification of NPC1 mutant complementation. Transiently transfected M12 cells were 
costained with NPC1 antibody and filipin, then imaged via fluorescence microscopy. Cells were 
phenotyped for complementation based on filipin staining, and binned as having no complementation 
(dark gray), partial complementation (light gray), or full complementation (black). Mutants with at least 
10% full complementation were considered partially functional (A) while others were considered non-
functional (B). N=30-100 cells/group.  
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Figure 2.4: Characterization of partially functional human NPC1 mutants. (A) qRT-PCR 
quantification of NPC1 mRNA from HSFs derived from NPC1 patients. (B) Western blot of NPC1 protein 
from HSFs. (C) Quantification of NPC1 protein in (B). (D) Western blot of NPC1 HSFs treated with 
stabilizing compounds. (E) Quantification of NPC1 protein in (D). (F) Endo H treatment of M12 cells 
transiently expressing mutant NPC1 protein. Filled arrow indicates Endo H-resistant NPC1 while open 
arrows indicate Endo H-sensitive NPC1. Gly, glycerol; Vel, Velcade; PBA, phenylethane boronic acid. 
*p<0.05  
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Figure 2.5: Subcellular localization of NPC1 protein in patient-derived HSFs. Fibroblasts were 
costained with NPC1 (Cianciola et al.) and LAMP1 (red) antibodies, then imaged via fluorescence 
microscopy. LAMP1 exposure is the same in all images while NPC1 exposure is optimized for each 
mutant.  
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Figure 2.6: Effect of small molecule chaperones on human NPC1 mutant protein stability. (A) 
Western blot of NPC1 protein from NPC1I1061T and NPC1P887L HSFs treated with CFTR compound C4 for 
48hrs. (B) Quantification of NPC1 protein in (A). (C) Western blot of NPC1 protein from NPC1I1061T HSFs 
treated with FoldRx compounds for 48hrs. (D) Quantification of protein in (C). (E) Free cholesterol in 
NPC1 mutant HSFs treated with 10µM C4. (F) Free cholesterol in NPC1I1061T HSFs treated with 10µM 
FoldRx compounds. *p<0.05  
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Chapter 3: Generation and validation of the NPC1I1061T knock-in mouse model 
3.1 Introduction 
Development of proteostatic therapies for NPC1 disease requires testing candidate therapies in a 
suitable disease model. Many of the prominent neuropathological features of human NPC1 disease (e.g., 
neuronal lipid storage and progressive loss of Purkinje cells) are modeled in the BALB/c NPCnih (NPC1-/-) 
mouse. However, this model does not synthesize NPC1 protein and therefore is not amenable to 
proteostatic therapies (Morris et al., 1982; Pentchev et al., 1980; Shio et al., 1982). To address the need 
for an animal model in which to test proteostatic therapies for NPC1 disease, we generated a NPC1I1061T 
knock-in mouse model. 
 
3.2 Methods 
Generation of NPC1I1061T knock-in mice. The murine NPC1 genomic locus was inserted into a mouse 129 
BAC construct (BAC ID# bMQ-398C12). The I1061T mutation, ATA to ACA at aa 1061 in exon 21, was 
introduced via galK-based recombineering as previously described (Warming et al., 2005). A silent 
mutation was also introduced at aa 1058 (GCT to GCC, both alanine) to engineer an MspI restriction site 
for genotyping. A loxP site was inserted via recombineering (Lee et al., 2001) within a non-conserved 
region ~220 bp upstream of exon 12, eliminating a wild-type (WT) NdeI site. A loxP-frt-pGK-neomycin-frt 
expression cassette was inserted within a non-conserved region ~800 bp downstream of exon 20, serving 
as positive selection in ES cells.  Conditional deletion of exons 14-20 introduces a frameshift and multiple 
early stop codons, providing the option of conditional NPC1 knockout for future experiments. The 
targeting vector was generated from the engineered BAC using gap repair, then inserted into a plasmid 
vector containing a diphtheria toxin cassette for negative selection in 129 ES cells (Lee et al., 2001) and 
linearized for ES cell electroporation with AscI. PCR analysis was performed using an external primer 3ʹ′ 
of the short arm and an internal primer within the neomycin cassette. Southern blot analysis of NdeI or 
NdeI/HindIII digestion products confirmed homologous recombination in the ES cells. Cells were injected 
into C57BL/6 blastocysts and implanted in C57BL/6 mothers. Resulting chimeras were then bred with 
FLPeR C57BL/6 mice (Jackson Labs #003946) to excise the neo cassette. Excision was confirmed via 
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PCR and HindIII digestion. These mice were then backcrossed into the Jackson Labs C57BL/6 
background for 5 generations. Mice were kept in a controlled animal facility and given standard chow and 
water ad libitum. Weaning occurred between 3 and 4 weeks. Experimental procedures were approved by 
the Washington University Animal Studies Committee and were conducted in accordance with the USDA 
Animal Welfare Act and the Public Health Service Policy for the Humane Care and Use of Laboratory 
Animals. 
 
Genotyping. NPC1I1061T knock-in mice were identified via PCR-based genotyping method with the 
following primers: forward (5ʹ′-tgatctgcacacttggaaccgag-3ʹ′) and reverse (5ʹ′-cactgccttgagcagcatctcag-3ʹ′). 
Wild type (WT) NPC1 allele produced a 200 bp band while the knock-in allele produced a 234 bp band. 
MspI restriction digest also confirmed presence of the I1061T point mutation. 
  
Functional evaluation of mice. For animal survival studies, the general clinical condition of the mice was 
monitored daily. Mice were weighed weekly beginning at 4 weeks of age until they expired. Death was 
defined as either being found dead in the cage or the inability to eat or drink on their own, necessitating 
euthanasia. Cerebellar function was evaluated weekly by measuring retention time on a rotating drum at 
15 rpm (Langmade et al., 2006). For each run, cumulative retention time on the drum was determined for 
three consecutive attempts (a maximum of 180 seconds per attempt). Mice were tested in the morning 
and the afternoon, and the rotarod score determined as the highest cumulative retention time for an 
individual session. 
 
Real–time quantitative RT-PCR. Mice were euthanized, and liver and cerebellum were flash-frozen in 
liquid nitrogen and stored at -80oC. RNA was harvested by homogenization in Trizol reagent (Invitrogen) 
as per manufacturer protocol. cDNA libraries were made via the Superscript III First Strand Synthesis 
System (Invitrogen) with provided oligo dT primers. qRT-PCR analysis was performed with reported 
primer sequences (Gelsthorpe et al., 2008). Relative quantification of gene expression was performed 
using the comparative threshold (CT) method as previously described (Millard et al., 2005). Fold changes 
in mRNA expression level were calculated following normalization to 36B4. 
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Protein preparation and western blot analysis. Protein was harvested from flash-frozen liver and brain 
tissues as previously described (Newberry et al., 2003). Cultured cells were harvested in RIPA buffer (10 
mM Tris-Cl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 
and 140 mM NaCl) with Complete Protease Inhibitor Mixture (Roche) and 1 mM phenylmethylsulfonyl 
fluoride and incubated on ice for 10 minutes. Post-nuclear supernatant was obtained by centrifuging for 
10 minutes at 12,000g at 4oC. Protein concentration was quantified using the BCA Protein Assay Kit 
(Pierce). Non-boiled protein samples were resolved by 7.5% SDS-PAGE under reducing conditions. 
Proteins were transferred onto polyvinylidene difluoride (0.45 mm; Millipore) using a semi-dry 
electroblotter (Owl Scientific). Western blot analysis was performed using an affinity purified rabbit anti-
human NPC1 antibody at a dilution of 1:2500 (Millard et al., 2000) and rabbit anti-human HSP90 
(Enzo/Stressgene) at a dilution of 1:5000. Detection was performed by chemiluminescence using a 
peroxidase-conjugated donkey anti-rabbit IgG (Jackson Immunoresearch) at 1:5000. 
 
Endoglycosidase treatments. Liver and brain tissues were isolated and protein harvested as described 
previously (Newberry et al., 2003). Protein samples were incubated with Endoglycosidase H (New 
England Biolabs) or PNGaseF (New England Biolabs) for 7 hours at 37oC in 5mM sodium phosphate with 
1% NP-40. 
Hepatocyte isolation and cycloheximide treatment. Mouse hepatocytes were isolated from age P35 mice 
and cultured as previously described (Chen et al., 2000). At 24 hours after plating, cells were treated with 
30µg/mL cycloheximide (Sigma) in growth media for the indicated time periods. Thereafter, they were 
lysed and subjected to western blot-analysis as described above. 
Isolation of murine embryonic fibroblasts. Mouse embryos were isolated at day 13.5 and placed in PBS. 
The head and entrails were removed, and then the embryo was minced into small chunks. Chunks were 
transferred to a 50mL conical, and 1mL of trypsin (0.25% in EDTA) was added, pipetting to begin 
disaggregation. Another 0.5mL of trypsin was added and the tissue was digested 15 min at room 
temperature with occasional vortexing. The reaction was then neutralized with media (10% heat 
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inactivated fetal serum, 1% nonessential amino acids, and 150 µM 1-Thioglycerol in DMEM) and 
supernatant taken as sample. Samples were centrifuged at 1000rpm for 10min to pellet cells. Isolated 
cells were then plated into flasks, approximately 1.25 embryos per T150. 
Statistics. Statistical significance was calculated via two-tailed t-test using the Holm-Sidak method, with p 
<0.05 considered to be significant.  
 
3.3 Results 
NPC1I1061T knock-in mice have decreased lifespan, reduced body weight, and impaired motor function. To 
generate the targeting vector to introduce the I1061T point mutation into the murine NPC1 locus, we 
utilized a BAC construct and galK-based recombineering as described (Figure 3.1A).  Recombination 
events were confirmed in ES cells by restriction digest and Southern blotting (Figure 3.1B). ES cells 
harboring the mutant allele were then injected into C57BL/6 pregnant dams, and chimeras were bred with 
FLPeR C57BL/6 mice to excise the neomycin cassette.  Analyses were performed on offspring 
backcrossed a minimum of five generations into the C57BL/6 background. When compared to the NPC1-/- 
model, NPC1I1061T mice live 59% longer, with an average lifespan of 125 days, consistent with expression 
of a partially functional NPC1I1061T protein (Figure 3.2A) Like NPC1-/- mice, NPC1I1061T mice have 
significantly lower body weight compared to their wild type (WT) littermates, and growth curves begin to 
diverge at 10 weeks, displaying progressive weight loss during latter stages of disease (Figure 3.2B). At 
approximately eight weeks of age, there is onset of a visible resting tremor in the NPC1I1061T mice, and by 
12 weeks the mice are no longer able to maintain balance on a rotating rod, a test of motor coordination 
(Figure 3.2C). 
 
The murine NPC1I1061T protein is unstable and retained in the ER. In human NPC1 mutant fibroblasts the 
NPC1I1061T protein is misfolded and targeted for proteasomal degradation. As a result, the half-life of the 
mutant NPC1 protein is decreased, and the small amount of protein that is present is predominantly 
localized to the ER (Gelsthorpe et al., 2008). We hypothesized that the murine NPC1I1061T protein has the 
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same defect. To determine whether tissues from NPC1I1061T mice have decreased NPC1 protein 
accumulation, we performed western blotting of liver and brain homogenate. NPC1I1061T mice showed 
dramatically decreased levels of NPC1 protein in both tissues compared to WT, which is not proportional 
to the slightly decreased expression of NPC1 mRNA (Figure 3.3A-C). In addition, the NPC1I1061T protein 
demonstrated an enhanced electrophoretic mobility, suggesting a less mature glycosylation state. Most of 
the NPC1I1061T protein migrates as a ~140kDa band, which is the predicted weight of unmodified NPC1, 
while a small proportion of presumably glycosylated NPC1 protein appears as higher molecular weight 
bands. To determine whether murine NPC1I1061T protein has decreased stability, we isolated hepatocytes 
from WT and NPC1I1061T littermates, treated these primary cells with cycloheximide (CHX) to block new 
protein synthesis, and quantified levels of NPC1 protein by western blotting. Whereas 63% of WT NPC1 
protein was remaining after treatment, NPC1I1061T protein levels decreased to 33% (Figure 3.3D, E). 
Digestion of liver and brain homogenate with Endo H, which removes immature N-linked glycan residues, 
revealed that a majority of murine NPC1I1061T protein lacks mature glycosylation, indicating that it has 
been retained in the ER due to misfolding (Figure 3.3F). We also found that digested NPC1I1061T protein 
from brain homogenate has a higher molecular weight compared to liver homogenate, indicating that 
NPC1I1061T protein may have additional post-translational modifications in this organ, such as O-linked 
glycosylations. It is also important to note that the buffers used in the digest reaction alter the apparent 
mobility of NPC1 bands (Gelsthorpe et al., 2008), which explains the difference in the appearance 
between 3.3A and 3.3F. To determine whether the subcellular localization of NPC1I1061T protein is altered, 
we performed immunofluorescence staining in murine embryonic fibroblasts (MEFs; Figure 3.4). In WT 
MEFs, NPC1 co-localized with a LAMP1-positive, filipin-negative endolysosomal compartment, while in 
NPC1I1061T MEFs the mutant protein displayed a reticular staining pattern that is distinct from filipin-
positive lysosomes and is most consistent with ER localization. Together, these data indicate that murine 
NPC1I1061T protein, like the human mutant protein, is misfolded and targeted for ER associated 
degradation, preventing its proper targeting to endolysosomes. 
 
3.4 Discussion 
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We generated and characterized a novel NPC1 disease model, the NPC1I1061T knock-in mouse. 
Introduction of the I1061T missense mutation into the murine NPC1 locus destabilized the NPC1 protein 
and prevented its targeting to late endosomes/lysosomes. This result mimics the effects of this mutation 
in human fibroblasts. Phenotypically, the reduced lifespan, altered growth curves, and progressive decline 
in motor coordination were all consistent with NPC1 disease. These effects were milder than the severe 
infantile form of the disease modeled by the BALB/c NPCnih mouse.  
While WT and NPC1I1061T mice express similar levels of NPC1 mRNA, NPC1 protein levels are 
sharply reduced in liver and brain tissues from NPC1I1061T mice. The reduced half-life of the murine 
NPC1I1061T protein and the Endo H sensitivity pattern, indicating failure of the mutant protein to process to 
a post-ER compartment, is consistent with our earlier finding of reduced NPC1 protein stability in 
NPC1I1061T human skin fibroblasts and demonstrates that a majority of NPC1I1061T protein is misfolded and 
targeted for degradation (Gelsthorpe et al., 2008). The immunofluorescence staining pattern for the 
NPC1I1061T protein, which revealed that the majority of the mutant protein failed to co-localize with late 
endosomal/lysosomal marker LAMP1, further supports a model in which the mutant protein is retained 
within the ER. Intriguingly, we found differences in the electrophoretic mobility of WT and NPC1I1061T 
proteins from liver and brain tissues. Endo H and PNGaseF digestion of WT protein from these tissues 
suggests that the NPC1 protein may be differentially glycosylated in the liver and brain. The NPC1I1061T 
protein is resistant to both glycosidases in both tissues which suggests that its impaired folding prevents 
trafficking through the ER and addition of N-linked sugar residues. The higher molecular weight of 
NPC1I1061T in brain tissue suggests this protein may be subject to other post-translational modifications. At 
present, the relevance of such tissue-specific differences in protein modification to normal physiology or 
disease pathophysiology is unknown. 
  
	   26	  
 
Figure 3.1: Knock-in strategy for the NPC1I1061T mouse model. (A) Diagram of the knock-in targeting 
vector, the WT NPC1 allele, and the resulting recombined allele. (B) Restriction digest of genomic DNA 
followed by Southern blotting in ES cells. Genomic DNA from WT and NPC1+/I1061T mice was digested 
with NdeI and HindIII to produce a 6.1kb band from the WT allele and a 7.6kb band from the knock-in. 
DTA, diphtheria toxin cassette; Neo, neomycin cassette. 
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Figure 3.2: Natural history of NPC1I1061T mice. (A) Survival of NPC1I1061T mice in days is compared to 
the NIH NPC1-/- model. NPC1-/- (N=8), NPC1I1061T (N=12). (B) Weights of wild-type (WT), heterozygous 
(NPC1+/I1061T), and homozygous (NPC1I1061T) mice recorded weekly beginning at week 4. (C) Rotarod 
testing was used to evaluate motor function on a constant 15rpm rotating drum. Values reported are the 
sum of the time on rotarod for three consecutive attempts.  *p<0.05, **p<0.001  
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Figure 3.3: In vivo characterization of NPC1 protein in NPC1I1061T tissues. (A) Western blot of WT 
(50µg protein) and NPC1I1061T (200µg protein) tissue homogenate from age P28 mice. (B) Quantification 
of western blot in (A). (C) qRT-PCR analysis of NPC1 mRNA from P28 WT and NPC1I1061T tissue. (D) 
Western blot of hepatocytes isolated from P35 mice, treated with 30ug/mL cycloheximide over an 8 hour 
time course. (E). Quantification of western blot in (D). (F) Western blot of WT (200µg) and NPC1I1061T 
(400µg liver, 500µg brain) tissue homogenate treated with Endo H and PNGase F. Filled arrow indicates 
Endo H-resistant NPC1 while open arrows indicate Endo H-sensitive NPC1. *p<0.05 
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Figure 3.4: Subcellular localization of NPC1I1061T protein. (A) NPC1 (red) and free cholesterol (Filipin, 
blue) immunofluorescence staining of WT and NPC1I1061T MEFs. Exposure time for both channels is 
equivalent across cell types. NPC1 gain=750 with laser at 2%; Filipin gain=800 with laser at 2% (B) NPC1 
(red) and LAMP1 (Cianciola et al.) immunofluorescence staining of WT and NPCI1061T MEFs. Laser power 
for NPCI1061T is increased to 6% to balance channel brightness.  
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Chapter 4: Neurodegeneration in the NPC1I1061T knock-in brain 
4.1 Introduction 
 Loss of NPC1 protein function results in lysosomal lipid accumulation in the brain and peripheral 
tissues (Butler et al., 1993; Dietschy and Turley, 2004; Goldin et al., 1992; Pentchev et al., 1985; Reid et 
al., 2004; Rodriguez-Lafrasse et al., 1994; Xie et al., 2000). Disruption of sterol trafficking is particularly 
toxic in the Purkinje neurons, since they are more sensitive to insufficient levels of ER sterol (Ko et al., 
2005). This stress causes the Purkinje neurons to upregulate cytokine expression and autophagic 
pathways, resulting in neurodegeneration (Ko et al., 2005; Li et al., 2005; Lopez et al., 2012; Vanier, 
2010). The NPC1-/- mouse is characterized by progressive, stereotypic Purkinje cell loss in the 
cerebellum, antecedent to motor dysfunction, which is a neuropathological hallmark of the disease 
(Vanier, 2010). Neurodegeneration is accompanied by astrogliosis, inflammatory gene expression, and 
storage of cholesterol-derived and sphingolipid species in the brain and peripheral tissues, mirroring the 
changes reported in human NPC1 disease (Cologna et al., 2014; Vanier, 1983, 1999). We hypothesized 
that the NPC1I1061T knock-in mouse would have delayed Purkinje cell death compared to the NPC1-/- 
mouse because of the expression of partially functional NPC1 protein. 
 
4.2 Methods 
Immunohistochemistry. Mouse cerebellar tissue was harvested at indicated timepoints. Brain tissue was 
perfused, sectioned, and stained as described previously (Davidson et al., 2009; McGlynn et al., 2004).  
 
Real–time quantitative RT-PCR. Mice were euthanized, and liver and cerebellum were flash-frozen in 
liquid nitrogen and stored at -80oC. RNA was harvested by homogenization in Trizol reagent (Invitrogen) 
as per manufacturer protocol. cDNA libraries were made via the Superscript III First Strand Synthesis 
System (Invitrogen) with provided oligo dT primers. qRT-PCR analysis was performed with reported 
primer sequences (Li et al., 2005; Liu et al., 2010). Relative quantification of gene expression was 
performed using the comparative threshold (CT) method as previously described (Millard et al., 2005). 
Fold changes in mRNA expression level were calculated following normalization to 36B4. 
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Statistics. Statistical significance was calculated via two-tailed t-test using the Holm-Sidak method, with p 




NPC1I1061T mice exhibit neuropathology characteristic of NPC1 disease. The progressive loss of motor 
coordination in NPC1 disease is a well-established consequence of the stereotypical Purkinje cell loss in 
the cerebellum. To determine whether the neurological phenotype we observed in the NPC1I1061T mice 
was associated with Purkinje cell death, we performed Calbindin D immunohistochemistry to visualize 
these neurons in cerebellar sections from postnatal day 63 (P63) and day 105 (P105) mice. In contrast to 
WT littermates, cerebella from NPC1I1061T mice showed progressive, age-dependent loss of Calbindin D 
staining, predominantly in the anterior lobules, indicating loss of Purkinje cells (Figure 4.1A). Loss of 
Purkinje cell bodies was accompanied by swelling of dendrites in the surviving cells, which is indicative of 
the neuronal dysfunction that typifies NPC1 disease (Figure 4.1B). In the cerebella of P63 and P105 
mice, there was significant loss of Purkinje cells in anterior (P63, 58% reduction, p <0.01; P105, 91% 
reduction, p <0.001) and posterior (P105, 65% reduction, p <0.001) lobules, but no appreciable Purkinje 
cell loss in lobule X, which is generally preserved even in end-stage disease (Figure 4.1D) (Davidson et 
al., 2009; Langmade et al., 2006). The progressive Purkinje cell loss was also reflected in the age-
dependent reduction in Calbindin D mRNA expression (Figure 4.1D). While the distribution of Purkinje cell 
loss in the NPC1I1061T mice was similar to that observed in the NPC1-/- model, the degree of Purkinje cell 
loss at P63 was less severe than in similarly aged NPC1-/- mice, which is consistent with delayed onset of 
impaired motor coordination in the knock-in compared to the knockout model (Langmade et al., 2006).  
A biochemical hallmark of NPC1 disease is the lysosomal accumulation of gangliosides free 
cholesterol in the brain (Butler et al., 1993; Dietschy and Turley, 2004; Goldin et al., 1992; Pentchev et 
al., 1985; Reid et al., 2004; Rodriguez-Lafrasse et al., 1994; Xie et al., 2000). To examine whether 
NPC1I1061T CNS neurons exhibited the lipid storage phenotype, brain sections of the neocortex and 
hippocampus from P28, P63, and P105 NPC1I1061T mice were sectioned and stained with GM2 
ganglioside antibody and filipin to label free cholesterol. Neurons in the neocortex and hippocampus 
	   32	  
accumulated unesterified cholesterol (Figures 4.2A, C) and GM2 ganglioside (Figures 4.2B, D), a 
complex glycosphingolipid that invariably accompanies cholesterol storage in NPC1 disease (Walkley and 
Suzuki, 2004). 
 
Cytokine activation and inflammation in tissues in NPC1I1061T mice. A prominent feature of NPC1 disease 
models is profound inflammatory changes, particularly in brain tissue (Langmade et al., 2006). We 
quantified inflammatory gene expression by performing qRT-PCR on mRNA isolated from brain and liver 
tissue from NPC1I1061T mice and WT littermates at P28, P63, and P105 (Figure 4.3). NPC1I1061T 
cerebellum tissue showed increased apolipoprotein E (ApoE) and Glial Fibrillary Acidic Protein (GFAP) 
expression compared to WT that was significant at P63 and P105,  (For P63 and P105, p<0.05), which is 
consistent with glial activation known to occur in response to neuronal cell death in NPC1 disease (Figure 
4.3A; Baudry et al, 2003). This was accompanied by a dramatic increase in expression of cytokines 
(TNFα and MIP1α) and markers of microglial activation (CD68 and CD11c), particularly late in disease 
progression (Figure 4.3B). A similar pattern of induction of inflammatory gene expression was present in 
liver tissue (Figure 4.3C). With the exception of apoE expression in the brain, no significant changes in 
cholesterol homeostatic gene expression were observed in either tissue (Figure 4.4). 
 
4.4 Discussion 
Our data demonstrate that NPC1I1061T mice exhibit progressive, stereotypic Purkinje cell loss in 
the cerebella, which is antecedent to motor dysfunction. This phenotype was less severe than in the 
NPC1-/- model, which is consistent with our hypothesis that the NPC1I1061T protein is partially functional in 
murine tissues. Purkinje neuron loss is most prominent in the anterior lobules of the cerebellum while 
those in lobule X appear to be protected from cell death. This pattern could be the result of increased 
expression of protective genes in lobule X. Studies in the NPC1-/- model have shown that neurons in the 
posterior zone have increased expression of HSP25 compared to anterior neurons. HSP25 function may 
confer Purkinje cell survival in NPC1I1061T mice by reducing ER stress caused by protein misfolding	  
(Sarna et al., 2003). Increased tyrosine hydroxylase activity in these cells may also have a protective 
effect by promoting neurotransmission (Sarna et al., 2003). 
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The increased expression of cytokines and astrogliosis we observed in NPC1I1061T mice support 
the current model that neuronal stress pathways are activated in the diseased neurons and cause 
autonomous cell death. While we report accumulation of cholesterol-derived and sphingoid species, we 
did not observe significant changes in expression of cholesterol homeostatic genes. This indicates that 
the partial function of the NPC1I1061T protein in the brain is sufficient to prevent upregulation of cholesterol 
biosynthetic pathways. These data demonstrate that NPC1I1061T mice have toxic lipid storage in brain 
tissues resulting in neuronal stress, eventually leading to Purkinje cell death and motor dysfunction. The 
neuronal phenotype we observe in the NPC1I1061T mice is consistent with both the NPC1-/- model and 
human disease.   
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Figure 4.1: Purkinje neuron loss in NPC1I1061T mice. (A) Cerebellar sections stained with Calbindin D 
(brown), a Purkinje cell marker, and Nissl counterstain (blue). (B) High magnification (63x) image of 
Purkinje cells from a P63 NPC1I1061T mouse. Asterisks denote Purkinje cells that are absent. Arrow 
indicates a swollen dendrite. (C) Quantification of Purkinje cells. Values are calculated as number of 
Purkinje cells per 100µm of linear length of the Purkinje layer, averaged from three independent sections 
(N=3-7/group). WT value is the average of three P63 and four P105 mice. (D) qRT-PCR quantification of 
Calbindin D mRNA in the brains of WT and NPC1I1061T mice, ages P28, P63, and P105 (N=4/group).  
*p<0.01, **p<0.001  
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Figure 4.2: Visualization of lipid storage in the NPC1I1061T mouse brain. Neocortex sections (upper 
panels) and hippocampus sections (lower panels) stained with filipin (A,C) and GM2 (B,D; Nissl blue 
counterstain). Images are representative of each group, ages P28, P63, and P105 (N=3-7/group). Scale 
bars=100 microns.  
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Figure 4.3: Inflammatory gene expression in NPC1I1061T brain and liver tissue. (A)  ApoE and GFAP 
mRNA expression in brain. (B) Expression of markers of cytokine activation (TNFα, MIP1α) and glial 
activation (CD68, CD11c) in brain. (C) Expression of markers of cytokine activation (TNFα, MIP1α) and 
macrophage activation (CD68, CD11c) in liver. Values are normalized to 36B4 and fold change is 
calculated relative to WT p28 values.  *p<0.5, **p<0.001 for NPC1I1061T vs. WT. 
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Figure 4.4: Cholesterol homeostatic gene expression in NPC1I1061T brain and liver tissue. qRT-PCR 
quantification of mRNAs in brain (A) and liver (B). Values are normalized to 36B4 and fold change is 
calculated relative to WT p28 values.  *p<0.5 for NPC1I1061T vs. WT.  
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Chapter 5: Lipid accumulation in NPC1I1061T knock-in tissues 
5.1 Introduction 
 The results described in Chapter 4 provide evidence that the NPC1I1061T mouse exhibits the same 
protein folding defect as human NPC1 patients harboring the I1061T allele. Previous studies have shown 
that multiple cholesterol-derived metabolites and sphingolipid species accumulate in liver and brain of the 
NPC1-/- mouse model, and an abundance of many species increases with disease progression (Fan et 
al., 2013; Goldin et al., 1992; Pentchev et al., 1980; Porter et al., 2010). The observed lack of maturely 
glycosylated NPC1I1061T protein in the lysosomal membrane and the neuronal storage of free cholesterol 
and ganglioside in the NPC1I1061T brain led us to hypothesize that this model would also accumulate a 
broad range of lipid classes in both the brain and peripheral tissues. To test this, we conducted 
metabolomic profiling of liver and brain tissues from NPC1I1061T mice and compared these results to the 
profile generated from the NPC1-/- mouse model.  
 
5.2 Methods 
Metabolomics. Sample preparation, instrumentation, and quantification of lipids were performed by 
tandem mass spectrometry as described previously (Fan et al., 2013). For NPC1I1061T heat maps, data 
was normalized to the average of the P28 WT values for each lipid, and Z scores for each lipid were 
generated as reported (Fan et al., 2013). Heat maps for the strain comparison were generated by 
normalizing data to C57/Bl6 WT, then calculating Z scores.  
 
Statistics. Statistical significance was calculated via two-tailed t-test using the Holm-Sidak method, with p 
<0.05 considered to be significant. In addition to the t-test, a Bonferonni test was applied to all 
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5.3 Results 
Lipid accumulation in tissues of NPC1I1061T mice. To determine whether the I1061T missense mutation led 
to a similar lipid storage phenotype, we broadly surveyed cholesterol-derived metabolites and 
sphingolipid de novo and recycling pathways in liver and brain tissue from the NPC1I1061T, NPC1I1061T/WT, 
and WT littermates (P14, P28, P63, and P105) and from NPC1-/- mice and WT littermates (P28, P63, and 
P105). Lipid classes quantified by tandem mass spectrometry included sphingoid bases, ceramides, 
sphingomyelins, mono- and dihexosylceramides, gangliosides, sulfatides, unesterified and esterified 
cholesterol, and oxysterols. The metabolomic profiles of brain and liver tissues from NPC1+/I1061T and WT 
littermates were very similar, which is consistent with previous profiling of heterozygotes in the NPC1-/- 
mouse strain (Figures 5.1, 5.2) (Fan et al., 2013). The only significant differences were increased 
cholesteryl ester species (CE 16:0, 18:0 and 18:1) in brain tissue in P14 and P28 NPC1+/I1061T mice 
(Figure 5.2B). By contrast, metabolomic profiling revealed marked differences between NPC1I1061T mice 
and age-matched WT littermates (Figures 5.1 and 5.2, Table 5.1). A broad range of lipids accumulated in 
the liver tissue of P14 NPC1I1061T mice: lactosylceramides  (LC 16:0 and 18:0), monohexosylceramides 
(MC 16:0, 20:0, 22:0, 24:0 and 24:1), sphingomyelins (SM 16:0, 18:0 and 24:0), sphingoid bases 
(sphinganine and sphingosine), gangliosides (GM2 16:0 and 18:0; GM3 16:0), unesterified cholesterol 
and 24(S)-hydroxycholesterol (Figure 5.1). The profound lipid storage in the suckling P14 mice likely 
reflects the high lipid content of the mouse milk (Silverman et al., 1992) since the lipid storage partially 
resolved after the mice were weaned at P21. In the liver tissue of older NPC1I1061T mice, there was age-
dependent accumulation of multiple sphingolipid species. Significant increases were found among 
ceramide (CER 24:0), monohexosylceramides (MC 16:0, 20:0, 22:0, 24:0 and 24:1), lactosylceramides 
(LC 20:0 and 22:0), sphingomyelins (18:1, 24:0), sphingosine, and gangliosides (GM2 16:0, GM2 22:0, 
and GM3 16:0) (Figure 5.1A). The sphingolipid accumulation was accompanied by significant increases in 
unesterified cholesterol, 24(S)-hydroxycholesterol, and 3β,5α,6β-cholestan-triol (Figure 5.1A, Table 5.1). 
Sphingolipids were also elevated in the brain tissue of the NPC1I1061T mice with significant increases 
found in lactosylceramides (LC 20:0), sulfatide (ST 20:0), sphinganine, and GM3 ganglioside (GM3 18:0) 
species (Figure 5.2). No significant differences in cholesterol or oxysterol species were detected in bulk 
brain tissue. 
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 While the sphingolipid and cholesterol storage phenotype in the NPC1I1061T mice was consistent 
with findings previously reported in the NPC1-/- mice, we were intrigued by the observation that NPC1I1061T 
mice principally accumulate monohexosylceramides and lactosylceramides in brain and liver tissues, 
whereas NPC1-/- mice store relatively more gangliosides (GM2 and GM3) (Fan et al., 2013). To assess 
whether the distinct lipid storage patterns reflected the difference between a partially functional NPC1 
missense mutation and a null mutation or differences in genetic background – NPC1I1061T and NPC1-/- 
mice are hosted in the C57BL/6 and BALB/C strains, respectively – we obtained brain and liver tissues 
from NPC1-/- mice backcrossed into the C57BL/6 background. Metabolomic profiling was performed in 
P49 NPC1-/- mice in both genetic backgrounds and demonstrated that, while there are only minor 
differences between the BALB/C and C57BL/6 WT lipid profiles, livers from C57BL/6 NPC1-/- mice 
accumulate more ceramides (CER 16:0, 18:0, 20:0, 24:1), monohexosylceramides (MC 22:0, 24:0), 
sphingomyelins (SM 16:0, 18:0, 20:0, 24:0), sphingoid bases (SPH, S’PH, 3-keto S’PH), gangliosides 
(GM2 16:0, 18:0, 22:0; GM3 16:0, 22:0), free cholesterol, 24(S)-hydroxycholesterol, 4β-
hydroxycholesterol, and cholesterol ester (18:1) compared to their BALB/C NPC1-/- counterparts (Figure 
5.3, Table 5.2). Fewer differences were seen in brain tissue, where C57BL/6 NPC1-/- mice accumulate 
more ceramide 24:1, lactosylceramide 24:1, and 3β,5α,6β-cholestan-triol (Figure 5.3, Table 5.2).  
 
5.4 Discussion 
 CNS lipid storage is central to the pathophysiology of NPC1 disease and precedes the 
inflammation and microglial activation that accompany neuronal loss (Reid et al., 2004). Metabolomic 
analysis of brain tissue in NPC1I1061T knock-in mice revealed age-dependent accumulation of a broad 
range of sphingolipid classes, notably sphingoid bases, mono- and dihexosylceramides, sphingomyelins 
and gangliosides. This pattern of storage is similar to brain tissue profile previously reported for NPC1-/- 
mice (Fan et al., 2013), demonstrating that the knock-in mouse faithfully models NPC1 disease. Although 
the general consensus is that the primary defect in NPC1 disease is impaired endolysosomal cholesterol 
export, the cholesterol accumulation is invariably accompanied by secondary storage of sphingolipids 
(Goldin et al., 1992; Pentchev et al., 1984; Pentchev et al., 1980; Vanier, 1983, 1999), perhaps due to the 
well-established biophysical association of cholesterol and sphingolipids in membrane bilayers. The 
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finding that miglustat, an iminosugar inhibitor of glucosylceramide synthase, provides neuroprotection in 
NPC1 animal models implies a role for sphingolipid storage in the disease pathogenesis (Zervas et al., 
2001). In contrast to the sphingolipid species, unesterified cholesterol levels are not elevated in bulk brain 
tissue. Rather, cholesterol storage is evident only by cytochemical analysis of brain tissue sections, 
predominantly in nuclei containing large neurons that have high obligate rates of cholesterol flux 
(Dietschy and Turley, 2004).  
The NPC1I1061T mice similarly exhibit profound lipid storage in peripheral tissues that is a 
prominent feature in NPC1 animal models and human NPC1 disease (Fan et al., 2013; Maue et al., 2012; 
Pentchev et al., 1980; Somers et al., 2001; Vanier, 1983). As in the brain tissue, sphingolipid storage in 
liver tissue steadily increases from P28 to P105, which correlates with disease progression. In contrast to 
brain tissue, this accumulation is accompanied by increased unesterified cholesterol in bulk tissue. Along 
with increased cholesterol stores, there is an attendant elevation of 3β,5α,6β-cholestan-triol, a non-
enzymatic oxidation product that is an NPC1-specific biomarker of disease  (Jiang et al., 2011; Porter et 
al., 2010), which reflects the unique intersection of elevated unesterified cholesterol and oxidative stress 
in NPC1 disease	   (Smith et al., 2009; Zampieri et al., 2008; Zhang et al., 2008). An unexpected finding 
was the massive lipid storage in the suckling P14 knock-in mice. The elevation was transient, since 
cholesterol and sphingolipid content were reduced following weaning (e.g. in P28 mice). This result 
strongly implicates the high lipid content of the mouse milk	   (Silverman et al., 1992) causes this 
phenotype. Moreover, the lipid storage in the suckling mice was observed in liver but not brain tissue, 
further supporting an exogenous origin for the lipid, since dietary cholesterol does not cross the blood-
brain barrier	   (Dietschy and Turley, 2004). The lipid storage phenotype in liver tissue in the neonatal 
knock-in mice closely mirrors the profound cholesterol storage in human NPC1 neonates, approximately 
half of whom present with prolonged jaundice or hepatosplenomegaly	  (Vanier, 2010). 
The genetic background of NPC1I1061T mice appears to have important effects on the NPC1 
disease phenotype. Initially, the knock-in mice were backcrossed in the BALB/c background to permit 
comparison with the NPC1-/- mice in the same background. While the NPC1 disease phenotype (e.g., 
tremor and reduced lifespan) was readily apparent in the mice in the mixed 129/Bl6 background, this 
phenotype was markedly attenuated once backcrossed into the BALB/c background (unpublished 
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observations). In this genetic background, there was no overt neurological disease. Disease was only 
detectable neuropathologically in 6-month old mice (not shown), prompting us to re-establish the knock-in 
mice in the more permissive C57Bl/6 background. Consistent with this finding, metabolomic profiling of 
the NPC1-/- mice revealed significant differences in the extent of cholesterol and sphingolipid storage 
between the different genetic backgrounds. In comparison to NPC1-/- mice in the BALB/c background, 
NPC1-/- mice in the C57Bl/6 background displayed an increased accumulation of ceramide species, 
sphingomyelins, sphingoid bases, gangliosides, free cholesterol, and oxysterols in peripheral tissues. We 
hypothesize that the BALB/c strain harbors a modifier gene that confers protection against NPC1 disease	  
(Collins et al., 2006). This putative modifier gene could help stabilize the NPC1I1061T protein in the ER, 
possibly through modulating endogenous chaperones  (Yang et al., 2013). NPC1I1061T protein would have 
more time to achieve proper conformation for entry into the post-ER secretory pathway and ultimately be 
targeted to endolysosomes. Alternatively, the modifier gene might act to facilitate endolysosomal 
cholesterol release through NPC1-independent trafficking pathways	   (Abi-Mosleh et al., 2009; Cianciola et 
al., 2013). This variable penetrance of the NPC1 phenotype in the different genetic backgrounds will 
provide an opportunity in future studies to identify modifier genes that contribute to NPC1I1061T protein 
stabilization. 
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Figure 5.1: Lipidomic analysis of NPC1I1061T liver. Lipid and sterol species were quantified from liver 
homogenate via LC/MS/MS, and heat maps were generated as described in Methods. Each tile 
represents a single animal, N=4 per group. Z scores are represented in gradient color scale with green 
representing lowest value (-3), black representing “0” value, and red representing highest value (+3). 
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Figure 5.2: Lipidomic analysis of NPC1I1061T brain. Lipid and sterol species were quantified from brain 
homogenate via LC/MS/MS, and heat maps were generated as described in Methods. Each tile 
represents a single animal, N=4 per group. Z scores are represented in gradient color scale with green 
representing lowest value (-3), black representing “0” value, and red representing highest value (+3).  
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Table 5.1: Lipidomic analysis of NPC1I1061T tissues. Fold change values of lipids quantified in liver (A) 
and brain (B) from NPC1I1061T mice compared to WT mice of the same age. N=4 per group. Blue, p<0.05; 
green, p<0.01; purple, p<0.001; white, non-significant.  
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Figure 5.3: Lipidomic analysis of NPC1-/- C57BL/6 and BALB/C strains. Lipid and sterol species were 
quantified in liver and brain homogenate from P49 NPC1-/- C57BL/6 and NPC1-/- BALB/C mice via 
LC/MS/MS, and heat maps were generated as described in Methods. Values were normalized to WT 
C57BL/6. Each tile represents a single animal, N=3-5 per group. Z scores are represented in gradient 
color scale with green representing lowest value (-3), black representing “0” value, and red representing 
highest value (+3).   
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Table 5.2: Lipidomic analysis of NPC1-/- C57BL/6 and BALB/C strains. Fold change values of lipids 
quantified in Figures 5.2 and 5.3 are normalized to WT C57BL/6 mice. Significance was calculated via 
student’s T-test, comparing NPC1-/- mice to their strain WT littermates. Blue, p<0.05; green, p<0.01; 
purple, p<0.001; white, non-significant.  
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Chapter 6: Rescue of murine NPC1I1061T protein misfolding via HDAC inhibition 
6.1 Introduction 
In recent studies we showed that treatment of human NPC1 mutant cells with certain HDACi, 
including the non-selective HDACi suberanilohydroxamic acid (SAHA), leads to clearance of excess 
cholesterol and other lipids from late endosomes/lysosomes and corrects the overall defect in cholesterol 
regulation	  (Pipalia et al., 2011). These changes were accompanied by increased expression of NPC1I1061T 
mutant protein. The mechanism of HDACi-inducted NPC1 stability is yet unclear, and could be due to 
altered transcription of proteostatic regulators of NPC1 or deacetylation of proteins involved in 
degradation of NPC1I1061T. One of the goals of generating the NPC1I1061T knock-in mouse is to produce a 
suitable model to test candidate proteostatic therapies, and we predict that this model will respond to 
treatments previously validated in human cell culture models of NPC1 disease. 
 
6.2 Methods 
Treatment of NPC1 fibroblasts with SAHA. WT and NPC1I1061T mouse embryonic fibroblasts (MEFs) were 
plated in 10 cm tissue culture plates in growth medium supplemented with 10% FBS. After 24 hrs 
incubation the cells were treated with 10 µM SAHA or DMSO (vehicle control) for 72 hrs in growth 
medium supplemented with 5.5% FBS, then stained with filipin as described in Chapter 2. 
 
6.3 Results 
Treatment with histone deacetylase inhibitors (HDACi) corrects the cholesterol storage phenotype in 
NPC1I1061T murine embryonic fibroblasts (MEFs). To determine whether the murine NPC1I1061T protein in 
the knock-in mice responded in a similar manner as human NPC1I1061T fibroblasts to a proteostatic 
therapy, we isolated MEFs from day 13.5 NPC1I1061T and WT littermate embryos and treated them with 
SAHA. In comparison to DMSO vehicle controls, SAHA-treated NPC1I1061T MEFs had reduced free 
cholesterol storage as determined by filipin staining (Figure 6.1A). The filipin labeling of late 
endosomes/lysosomes was quantified as described previously	   (Pipalia et al., 2011), and a significant 
reduction in stored cholesterol was observed (Figure 6.1B). A similar effect was observed in WT cells in 
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which we have previously shown that half of newly synthesized NPC1 is normally degraded	   (Gelsthorpe 
et al., 2008).  
 
6.4 Discussion 
The NPC1I1061T knock-in mouse provides a unique tool to assess candidate proteostatic therapies 
in vivo. Previous cell-based studies have shown that treatment with HDACi reduce cholesterol storage 
and increase NPC1 protein expression in human NPC1I1061T fibroblasts. To demonstrate that the murine 
NPC1I1061T protein is stabilized by HDACi, akin to human NPC1, we treated NPC1I1061T murine embryonic 
fibroblasts with SAHA (Vorinistat)	   (Kim et al., 2007; Munkacsi et al., 2011; Pipalia et al., 2011). We show 
that in MEFs derived from the knock-in mice, SAHA treatment similarly rescues the cholesterol trafficking 
phenotype. Together with the biochemical and immunofluorescence analysis of the NPC1I1061T protein in 
the mouse tissues, these data indicate that the cellular behavior of the mutant protein closely models that 
of the most common disease-causing mutation in the human NPC1 locus	   (Gelsthorpe et al., 2008) and 
provides proof-of-concept that the mouse model will respond similarly to interventions that stabilize the 
human NPC1I1061T protein. 
  
	   50	  
 
Figure 6.1: Effect of SAHA treatment on lysosomal cholesterol in NPC1I1061T MEFs. (A) Fluorescent 
images of cells treated with SAHA or DMSO vehicle and stained with filipin. (B) Quantification of 
lysosomal filipin staining normalized to NPC1I1061T DMSO. Values represent the average of 3 
experiments. *p<0.05  
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Chapter 7: Concluding remarks and future directions 
 In this dissertation I have demonstrated that several disease-causing mutations within the 
cysteine-rich domain of NPC1 retain partial function and are amenable to treatment with proteostatic 
therapies. To generate an in vivo model in which to test candidate therapies, we created the NPC1I1061T 
knock-in mouse model. This model is unique in that it expresses a protein that is not only relevant to 
human disease, but also is fully characterized as a misfolded and partially functional protein. This model 
not only serves as a faithful model for pre-clinical evaluation of targeted proteostatic therapies, but also a 
genetic tool with which we can determine the proteostatic environment of NPC1 in vivo. 
 
Future development of high-throughput screening for proteostatic therapies. As the candidate chaperone 
screen presented here suggests, the use of small chemical libraries to discover potential therapeutics for 
NPC1 disease can result in limited success. Development of a high-throughput screen to test a chemical 
library of typical size (~500,000 compounds) would dramatically increase the potential hit-rate. The assay 
for this screen should have a primary screen that quantifies the amount of mutant NPC1 protein, 
preferably using cells expressing endogenous levels of NPC1 protein to avoid confounding results caused 
by ER stress or complementation of the phenotype by overexpression. A secondary screen to determine 
if treatment increases cholesterol trafficking function of mutant NPC1 protein would also be necessary. 
The mechanism of action for compounds that are selected from the secondary screen could be elucidated 
via fluorescence-based binding assays as shown in Ohgane, 2013. The goal of these studies would be to 
provide candidate molecules for in vivo testing of NPC1 therapies. 
 
Further characterization of the NPC1I1061T protein defect. In this work, I have shown that murine 
NPC1I1061T protein is unstable and does not appropriately localize the lysosome, similar to human 
NPC1I1061T. Future work in this area can elucidate whether murine NPC1I1061T is localized to the ER and 
degraded in the proteasome, confirming that the protein has a folding defect. Determining the half-life of 
NPC1I1061T in primary cells via metabolic labeling would also be useful for future pre-clinical studies, 
particularly in determining whether the protein is less stable in the brain than in peripheral tissues. 
Furthermore, characterization of post-translational modifications in the brain could provide insight for 
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potential regulators of NPC1 stability, since we see differential electrophoretic mobility between brain and 
liver upon glycosidase treatment. 
 
Future discovery of gene(s) responsible for strain difference of the NPC1I1061T phenotype. During the 
course of generating the NPC1I1061T knock-in mouse, we discovered that mice lost their overt clinical 
phenotype after five backcrosses (F5) into the BALB/C background. Histological staining of brain tissue 
from F5 six-month-old BALB/C NPC1I1061T mice showed minimal lipid accumulation and Purkinje cell 
death, and we did not observe any neurological tremor nor decrease in motor function (data not shown). 
These results lead us to conclude that BALB/C mice harbor at least one gene that modifies NPC1 stability 
and/or function. We are currently conducting GWAS studies in P14 mice of mixed BALB/C and C57BL/6 
background, utilizing the lipid storage phenotype we observed in the livers of suckling mice as our 
readout of NPC1 function. Gene regulators of NPC1 that we discover from these studies will be potential 
targets for both drug discovery and gene therapy for NPC1 disease.  
 
Determining the mechanism of SAHA’s effect on the NPC1 phenotype. We have shown that treating 
NPC1I1061T MEFs with the HDACi SAHA rescues the cholesterol trafficking phenotype, which is similar to 
results shown in HSFs (Pipalia et al., 2011). We are currently conducting experiments to determine 
whether rescue is due to an increase in NPC1I1061T protein. We are also interested in elucidating the 
mechanism by which SAHA increases NPC1I1061T protein accumulation. Previous work has shown that 
HDACi can decrease activity of ER chaperones, including HSP90, which could allow misfolded NPC1I1061T 
to escape ER quality control and localize to the lysosome (Budillon et al., 2005). Alternatively, the HDACi 
activity of SAHA could alter the transcription of genes that regulate NPC1 stability or function. RNA-seq 
and protein acetylation profiling in SAHA-treated cells would provide useful data to clarify how HDACi 
rescues the NPC1 phenotype.  
Our ultimate goal is to treat NPC1I1061T mice with several chemical chaperones, including 
HDACi’s, ryanodine receptor antagonists, and oxysterol derivatives. This mouse model will also be useful 
for testing efficacy of gene therapy to target regulators of the proteostatic network. The data presented in 
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this work demonstrate that the NPC1I1061T knock-in mouse is an ideal model in which to conduct pre-
clinical studies of proteostatic therapies for NPC1 disease. 
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